Clinical Trials
2 trialsNCT06613633 2026-04-29
Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
Fudan University
Completed
NCT04671303 2025-05-11
To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed